Sort
10,766 grants matching “checkpoint inhibitor”
Cancer Immunotherapy Clinical Trials
$890,340Julius Strauss · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Next Generation Cancer Immunotherapies to Defeat Melanoma
$889,199Antoni Ribas · University Of California Los Angeles · R35 · FY2024 · CA
Initiation of DNA Replication in Mammalian Cells
$888,597Mirit Aladjem · Division Of Basic Sciences - Nci · Z01 · FY2008 · CA
Using Clinical Pharmacology Principles to Develop New Anticancer Therapies
$887,976William Douglas Figg · Division Of Clinical Sciences - Nci · ZIC · FY2020 · CA
Identification of human tumor-associated antigens
$887,872Kwong Yok Tsang · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA
Advancing treatment and understanding of immunotherapy in glioblastoma
$885,236Nicholas A Butowski · University Of California, San Francisco · U19 · FY2021 · CA
Targeting Genetic and Metabolic Alterations in Distinct Subtypes of RCC
$885,117Ramaprasad Srinivasan · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Optimizing AAV delivery of bNAbs for HIV prevention
$881,378Matthew Ryan Gardner · Emory University · R01 · FY2025 · AI
Mechanisms and Optimal Combinations of Cisplatin Chemotherapy for Head and Neck Squamous Cell Carcinoma
$880,830Nicole Schmitt · National Institute On Deafness And Other Communication Disorders · ZIA · FY2017 · DC
UNLOCKING THE POTENTIAL OF IMMUNE CHECKPOINT INHIBITORS IN THE PAPILLARY RENAL CELL CARCINOMA SETTING
$879,847Unity Health Toronto · · FY2025 · Defense Health Agency
Oncolytic Polovirus, Immunotoxin, and Checkpoint Inhibitor Therapy of Gliomas
$879,333Darell D Bigner · Duke University · R35 · FY2019 · CA
Gut Microbiome and Cancer Immunotherapy Outcomes in Advanced Renal Cell Carcinoma
$876,059Veronika Fedirko · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Antiviral role of CD8+ T cells in ART-treated SIV-infected macaques
$875,289Guido Silvestri · Emory University · R01 · FY2017 · AI
Defining the features of T cell response to tumor and self-antigens as predictors of response to checkpoint therapy
$874,780Jane Hoyt Buckner · Benaroya Research Inst At Virginia Mason · R01 · FY2019 · CA
Radiation-induced translational control of gene expression
$872,517Philip Tofilon · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA
Molecular Pathogenesis of Neoplasia
$872,468John Heiss · National Institute Of Neurological Disorders And Stroke · ZIA · FY2025 · NS
Immuno-Targeted Therapy for Melanoma
$872,264Antoni Ribas · University Of California Los Angeles · R35 · FY2019 · CA
Center for Interventional Oncology
$871,672Bradford J Wood · Division Of Basic Sciences - Nci · ZID · FY2020 · CA
Immune selection of HIV-1 reservoir cells in human clinical trials
$871,246Mathias Lichterfeld · Brigham And Women'S Hospital · R01 · FY2025 · AI
The Evaluation of Novel Therapeutics for Genitourinary Malignancies
$871,023William Laurence Dahut · Division Of Clinical Sciences - Nci · ZIA · FY2017 · CA
Signal Transduction Events and the Regulation of Cell Growth
$870,159Jane B Trepel · Division Of Clinical Sciences - Nci · ZIC · FY2016 · CA
Bladder Cancer Program
$869,986Andrea Apolo · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
Impact of Interventions on Clonally Expanded Proviruses and Their RNA Expression
$869,203Mary Kearney · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
Activating Cell Death Pathways in Breast Cancer Cells
$867,532Stanley Lipkowitz · Division Of Clinical Sciences - Nci · ZIA · FY2021 · CA
Targeting Nucleotide Excision Repair Deficiency to Improve Bladder Sparing Treatment for Muscle Invasive Bladder Cancer
$866,727Kent W Mouw · Dana-Farber Cancer Inst · R01 · FY2025 · CA